CAS 1887014-12-1

Olutasidenib

CAS : 1887014-12-1

Olutasidenib (FT-2102), an IDH1 inhibitor (IC50: 21.2/114 nM), is studied for treating AML/MDS and can cross the blood-brain barrier.

Formule : C₁₈H₁₅ClN₄O₂

Degré de pureté : 98.57%

Couleur et forme : Solid

Masse moléculaire : 354.79

Ref: TM-T16384

Olutasidenib

CAS : 1887014-12-1

Formule : C₁₈H₁₅ClN₄O₂

Degré de pureté : 98%

Masse moléculaire : 354.7903

Ref: IN-DA01FTRO

Olutasidenib

CAS : 1887014-12-1

Olutasidenib

Degré de pureté : ≥98%

Masse moléculaire : 354.79g/mol

Ref: 54-BUP09469

Olutasidenib

CAS : 1887014-12-1

Formule : C₁₈H₁₅ClN₄O₂

Couleur et forme : Neat

Ref: TR-O299810

Olutasidenib

CAS : 1887014-12-1

Olutasidenib is a molecule that inhibits the platelet-derived growth factor receptor alpha (PDGFRα) and is being investigated as a treatment for chronic myeloid leukemia (CML). Olutasidenib binds to PDGFRα, which prevents the activation of the receptor. This blocks the signaling that leads to tumor progression and inhibits tumor growth. Olutasidenib has been shown to be safe in phase I/II trials, with no serious adverse effects reported.

Formule : C₁₈H₁₅ClN₄O₂

Degré de pureté : Min. 95%

Masse moléculaire : 354.79 g/mol

Ref: 3D-MAD01412